Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jan 13;15(4):618-623.
doi: 10.1093/ckj/sfac009. eCollection 2022 Apr.

Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?

Lauren Floyd  1 , Adam D Morris  1 , Alexander Woywodt  1 , Ajay Dhaygude  1
Affiliations
Editorial

Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?

Lauren Floyd et al. Clin Kidney J. .

Abstract

The association between cardiovascular (CV) disease and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is well documented. The recent work by Massicotte-Azarniouch et al. confirms the risk and adds to the existing evidence by describing the highest risk in the first 3 months after diagnosis. In this review, we aim to put their findings into perspective and formulate implications for the care of AAV patients. We discuss mechanisms for increased CV disease in AAV, including the impact of traditional risk factors and disease-related risks such as renal impairment and anti-myeloperoxidase (MPO) ANCA serotype. We also provide a brief primer on the impact of inflammatory-driven endothelial dysfunction and platelet activation on accelerated atherosclerosis in AAV patients. These features alongside the impact of disease activity and systemic inflammation provide potential explanations to why the incidence of CV events is highest in the first 3 months from diagnosis. We suggest future avenues of research, provide some suggestions to address and treat CV risk based on current evidence, and highlight the importance of addressing this topic early on. Addressing modifiable risk factors, dialogue with patients, patient information and a structured approach overall will be key to improve CV outcomes in AAV.

Keywords: cardiovascular; medication; prognosis; treatment; vasculitis.

PubMed Disclaimer

Figures

FIGURE 1:
FIGURE 1:
Pathogenic factors influencing CVD in AAV. BMI, body mass index.
See this image and copyright information in PMC

Comment in

References

    1. Dregan A, Charlton J, Chowienczyk P et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014; 130: 837–844 - PubMed
    1. Roman MJ, Shanker B-A, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399–2406 - PubMed
    1. Faurschou M, Mellemkjaer L, Sorensen IJ et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009; 60: 1187–1192 - PubMed
    1. Robson J, Doll H, Suppiah R et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials. Ann Rheum Dis 2013; 74: 177–184 - PubMed
    1. Bramlage CP, Kröplin J, Wallbach M et al. Management of cardiovascular risk factors in patients with ANCA-associated vasculitis. J Eval Clin Pract 2017; 23: 747–754 - PubMed

Publication types